Reviewing Immune Design Corp. (IMDZ)’s and Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s results

Both Immune Design Corp. (NASDAQ:IMDZ) and Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) are Biotechnology companies, competing one another. We will compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immune Design Corp. 2.20M 128.84 54.76M -1.14 0.00
Aurinia Pharmaceuticals Inc. N/A 1222.95 52.86M -0.63 0.00

Table 1 demonstrates Immune Design Corp. and Aurinia Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has Immune Design Corp. and Aurinia Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Design Corp. -2,489.09% -43.4% -40.3%
Aurinia Pharmaceuticals Inc. 0.00% 0% 0%

Dividends

Immune Design Corp. pays out an annual dividend of $0.22 per share while its dividend yield is 3.84%. Aurinia Pharmaceuticals Inc. does not pay a dividend.

Analyst Recommendations

In next table is given Immune Design Corp. and Aurinia Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Immune Design Corp. 0 2 0 2.00
Aurinia Pharmaceuticals Inc. 0 0 1 3.00

The upside potential is 1.37% for Immune Design Corp. with consensus price target of $5.93. Meanwhile, Aurinia Pharmaceuticals Inc.’s consensus price target is $15, while its potential upside is 139.23%. The information presented earlier suggests that Aurinia Pharmaceuticals Inc. looks more robust than Immune Design Corp. as far as analyst opinion.

Insider and Institutional Ownership

Institutional investors held 81.7% of Immune Design Corp. shares and 0% of Aurinia Pharmaceuticals Inc. shares. Insiders held 0.9% of Immune Design Corp. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Immune Design Corp. 0.17% 273.72% 338.35% 68.99% 97.63% 348.46%
Aurinia Pharmaceuticals Inc. -8.75% 4.29% 17.74% 12.31% 29.08% -3.67%

For the past year Immune Design Corp. has 348.46% stronger performance while Aurinia Pharmaceuticals Inc. has -3.67% weaker performance.

Summary

Aurinia Pharmaceuticals Inc. beats on 8 of the 12 factors Immune Design Corp.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.